 <h1>Artesunate Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Interactions</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to artesunate: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (sometimes severe; up to 65%), delayed hemolysis (up to 27%), thrombocytopenia (up to 18%), leukocytosis (up to 10%), posttherapy hemolytic anemia in travelers, mild and transient decrease in reticulocyte count</p><p><b>Common</b> (1% to 10%): Lymphopenia, neutropenia (sometimes severe), disseminated intravascular coagulation, leukopenia, reduced reticulocyte count, posttherapy hemolytic anemia in endemic areas</p><p><b>Uncommon</b> (0.1% to 1%): Agranulocytosis, reticulocytopenia, erythroblastopenia</p><p><b>Very rare</b> (less than 0.01%): Pure red cell aplasia</p><p><b>Frequency not reported</b>: Posttherapy hemolytic anemia (including cases requiring transfusion), immune-mediated hemolysis</p><p><b>Postmarketing reports</b>: Delayed hemolysis, immune hemolytic anemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased transaminase (up to 27%), hyperbilirubinemia (up to 14%)</p><p><b>Common</b> (1% to 10%): Jaundice, transient elevation in liver transaminases (AST, ALT)</p><p><b>Uncommon</b> (0.1% to 1%): Elevated liver enzymes</p><p><b>Rare</b> (0.01% to 0.1%): Hepatitis, calculous cholecystitis<sup>[Ref]</sup></p><p>Transient elevation in liver transaminases, nausea, vomiting, anorexia, and diarrhea have been reported commonly but it is unclear whether these events may have been symptoms of severe malaria.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Acute renal failure (up to 10%)</p><p><b>Common</b> (1% to 10%): Acute renal failure requiring dialysis (included dialysis, hemodialysis, peritoneal dialysis), elevated creatinine<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hemoglobinuria<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Acute respiratory distress syndrome, pneumonia, pulmonary edema, cough, nasal symptoms<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain/cramps, vomiting, nausea</p><p><b>Uncommon</b> (0.1% to 1%): Mild gastrointestinal disturbances</p><p><b>Rare</b> (0.01% to 0.1%): Elevated serum amylase, pancreatitis</p><p><b>Postmarketing reports</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, alopecia</p><p><b>Frequency not reported</b>: Stevens-Johnson syndrome, urticaria<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Significant neurologic impairments, dysgeusia, tinnitus (with or without decreased auditory function), dizziness, headache, lightheadedness, altered taste (metallic/bitter taste)</p><p><b>Very rare</b> (less than 0.01%): Peripheral neuropathy, paresthesia</p><p><b>Frequency not reported</b>: Loss of balance, hemiplegia/paresis, ataxia, tremor<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Frequency not reported</b>: Neuropsychiatric symptoms, confusion, restlessness<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pyrexia/fever, fatigue, malaise</p><p><b>Frequency not reported</b>: Generalized weakness<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, muscle disorders<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Pain at injection site<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Rhythm disorders (bradycardia, sinus arrhythmia), conduction disorders (QTc lengthening, abnormal sinoatrial conduction)</p><p><b>Rare</b> (0.01% to 0.1%): Arterial ischemia, hypertensive retinopathy</p><p><b>Frequency not reported</b>: Cardiac arrest, atrioventricular block, possible QT prolongation<sup>[Ref]</sup></p><p>At least 1 case of cardiac arrest has been reported in a patient with severe malaria with multiorgan failure; causality by this drug has not been established.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity (allergic) reactions</p><p><b>Rare</b> (0.01% to 0.1%): Severe allergic reaction (included urticarial rash, hypotension, pruritus, edema, dyspnea)</p><p><b>Postmarketing reports</b>: Hypersensitivity, anaphylaxis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Artesunate (artesunate)." Amivas, Frederick, MD. </p><p id="ref_2">2. World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/prequal/key-resources/prequalification-reports/whopars."   ([2020]):</p><h2>More about artesunate</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: miscellaneous antimalarials</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Malaria</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>